logo/base Created with Sketch.
logo echosens
en
chevron Contact
English version chevron
Change region

Bibliography

wave
  1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
  2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
  3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.
  4. Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228.
  5. Ginès P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology. 2016;1(3):256-260. doi:10.1016/S2468-1253(16)30081-4.
  1. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38 Suppl 1:2-6. doi:10.1111/liv.13682.
  1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. doi:10.1016/j.jhep.2018.09.014.
  2. Wong VW-S, Adams LA, de Lédinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. doi:10.1038/s41575-018-0014-9.
  1. Kwok R, Choi KC, Wong GL-H, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359-1368. doi:10.1136/gutjnl-2015-309265.
  1. Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11(4):92-94. doi:10.1002/cld.710.
  1. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16. doi:10.1038/s41572-018-0014-7.
  1. WHO. Guidelines for the Screening Care and Treatment of Persons with Hepatitis C Infection. April 2014. http://public.ebookcentral. proquest.com/choice/publicfullrecord.aspx?p=1975017. Accessed March 4, 2020.
  1. WHO. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed February 14, 2020.
  2. WHO. Department of HIV/AIDS, the Global Hepatitis Programme. World Hepatitis Day 2017, WHO guide on advocacy and communications. 2017. https://www.who.int/campaigns/hepatitis-day/2017/campaign-brief.pdf?ua=1
  1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi:10.1038/nrgastro.2017.109.
  1. Ahmad J, Lau. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. HMER. Published online February 2013:1. doi:10.2147/HMER.S9049.
  1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease: Estes et al. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466.
  2. Ofusu 2018
  3. Friedman, 2018
  4. Lanthier, 2018
  5. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018 Feb;113(2):175-194. doi: 10.1038/ajg.2017.469 . Epub 2018 Jan 16. PMID: 29336434 ; PMCID: PMC6524956.
  6. Rehm, J. et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta- analysis. Drug Alcohol Rev.29, 437–445 (2010).
  7. WHO. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed February 14, 2020.
  8. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18. PMID: 28427875.
  9. Lim JK, Flamm SL, Singh S, Falck-Ytter YT; Clinical Guidelines Committee of the American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology. 2017 May;152(6):1536-1543. doi: 10.1053/j.gastro.2017.03.017. PMID: 28442119.
  10. Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver International 2009;29:1500-1506.
  11. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013;58:65-72.
  12. Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, Garcia-Pagan JC, Bosch J. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013;8:e58742.
  13. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182-1191.
  14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367.
  15. Ferraioli G, Wong VW-S, Castera L, et al. Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol. 2018;44(12):2419-2440. doi:10.1016/j.ultrasmedbio.2018.07.008.
  16. Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11(1):1-30. doi:10.1007/s12072-016-9760-3.
  17. SmartExam: E. Bardou-Jacquet et al, Validation of the Continuous Controlled Attenuation Parameter (CAPc) using the MRI-PDFF as reference. EASL 2022 poster #FRI-228​.
  18. Cohen JC, et al. Science. 2011;332(6037): 1519- 1523.